# GO29365 (NCT02257567)

> A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

- Drugs tested: polatuzumab vedotin; polatuzumab vedotin plus obinutuzumab plus bendamustine
- Indication: relapsed/refractory follicular or diffuse large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02257567
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Lymphoma
- Interventions: Bendamustine; Obinutuzumab; Polatuzumab vedotin (Liquid); Rituximab; Polatuzumab vedotin (Lyophilized)
- Enrollment: 331
- Primary outcome: Phase Ib: Percentage of Participants With Adverse Events (AEs)
- Primary outcome: Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs
- Primary outcome: Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin
- Primary outcome: Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
- Primary outcome: Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)
- Primary outcome: Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)
- Primary outcome: Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
- Primary outcome: Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)
- Primary outcome: Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)
- Primary outcome: Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)
- Primary outcome: Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)

## Indexed commentary on GO29365 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=go29365-nct02257567

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02257567", "email": "<work email>"}; the inbox owner confirms by the emailed link.